Simon Brewster
University of Oxford
86 Papers
908 Citations
Simon Brewster is an academic researcher from University of Oxford. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 22, co-authored 86 publications. Previous affiliations of Simon Brewster include University of Bristol & Bristol Royal Infirmary.
Chat about Author
Papers
Urology and the Internet: an evaluation of internet use by urology patients and of information available on urological topics.
TL;DR: To determine the use of the Internet by urological patients for obtaining information about their disease, and to conduct an evaluation of Urological websites to determine the quality of information available.
115
Focal Therapy for Prostate Cancer: Possibilities and Limitations
Scott E. Eggener,Georg Salomon,Peter T. Scardino,Jean J.M.C.H. de la Rosette,Thomas J. Polascik,Simon Brewster +5 more
TL;DR: Prostate focal therapy is a promising and emerging treatment strategy for men with a low risk of cancer progression or metastasis and evaluation in formal prospective clinical trials is essential before this new strategy is accepted in clinical practice.
115
PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.
Andrew J. Vickers,Simon Brewster +1 more
TL;DR: PSA kinetics have no value for men with an untreated prostate: neither PSA velocity nor doubling time have any role in diagnosing prostate cancer or providing a prognosis for men before treatment.
104
PREOPERATIVE p53, bcl-2, CD44 and E-CADHERIN IMMUNOHISTOCHEMISTRY AS PREDICTORS OF BIOCHEMICAL RELAPSE AFTER RADICAL PROSTATECTOMY
Simon Brewster,Jon Oxley,Jon Oxley,Jon Oxley,Marialena Trivella,Marialena Trivella,Marialena Trivella,Clive D. Abbott,Clive D. Abbott,Clive D. Abbott,David Gillatt,David Gillatt,David Gillatt +12 more
TL;DR: Aberrant biopsy p53 is associated with a significantly worse outcome after radical prostatectomy than normal p53, highlighting a potential clinical role for p53.
102
Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder.
TL;DR: The data suggest the presence of a late-acting TSG located on 18q in TCC bladder cancer, which is a candidate gene since it lies within the region of most common deletion (18q21.3-qter).
75